{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:29:14Z","timestamp":1790832554566,"version":"4.1.0"},"reference-count":103,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is a nearly always incurable malignancy of plasma cells, so new approaches to treatment are needed. T-cell therapies are a promising approach for treating MM, with a mechanism of action different than those of standard MM treatments. Chimeric antigen receptors (CARs) are fusion proteins incorporating antigen-recognition domains and T-cell signaling domains. T cells genetically engineered to express CARs can specifically recognize antigens. Success of CAR-T cells (CAR-Ts) against leukemia and lymphoma has encouraged development of CAR-T therapies for MM. Target antigens for CARs must be expressed on malignant cells, but expression on normal cells must be absent or limited. B-cell maturation antigen is expressed by normal and malignant plasma cells. CAR-Ts targeting B-cell maturation antigen have demonstrated significant antimyeloma activity in early clinical trials. Toxicities in these trials, including cytokine release syndrome, have been similar to toxicities observed in CAR-T trials for leukemia. Targeting postulated CD19+ myeloma stem cells with anti-CD19 CAR-Ts is a novel approach to MM therapy. MM antigens including CD138, CD38, signaling lymphocyte\u2013activating molecule 7, and \u03ba light chain are under investigation as CAR targets. MM is genetically and phenotypically heterogeneous, so targeting of &gt;1 antigen might often be required for effective treatment of MM with CAR-Ts. Integration of CAR-Ts with other myeloma therapies is an important area of future research. CAR-T therapies for MM are at an early stage of development but have great promise to improve MM treatment.<\/jats:p>","DOI":"10.1182\/blood-2017-06-793869","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T01:00:20Z","timestamp":1505869220000},"page":"2594-2602","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":185,"title":["Chimeric antigen receptor T-cell therapies for multiple myeloma"],"prefix":"10.1182","volume":"130","author":[{"given":"Lekha","family":"Mikkilineni","sequence":"first","affiliation":[{"name":"Medical Oncology Fellowship Program and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Kochenderfer","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111904432732300_B1","author":"American Cancer Society","year":"2017"},{"issue":"4","key":"2019111904432732300_B2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","article-title":"Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity","volume":"51","author":"Cornell","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"2019111904432732300_B3","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111904432732300_B4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2019111904432732300_B5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2019111904432732300_B6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"issue":"7","key":"2019111904432732300_B7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2019111904432732300_B8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","article-title":"Designing chimeric antigen receptors to effectively and safely target tumors","volume":"33","author":"Jensen","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"13","key":"2019111904432732300_B9","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111904432732300_B10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111904432732300_B11","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3109\/10428194.2015.1052808","article-title":"When to recommend allogeneic transplant in multiple myeloma","volume":"56","author":"Gertz","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111904432732300_B12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2015.325","article-title":"Allogeneic stem cell transplantation for multiple myeloma: is there a future?","volume":"51","author":"Dhakal","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111904432732300_B13","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst","year":"1997","journal-title":"Blood"},{"issue":"29","key":"2019111904432732300_B14","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111904432732300_B15","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","article-title":"Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors","volume":"65","author":"Noonan","year":"2005","journal-title":"Cancer Res"},{"issue":"288","key":"2019111904432732300_B16","doi-asserted-by":"crossref","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","article-title":"Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma","volume":"7","author":"Noonan","year":"2015","journal-title":"Sci Transl Med"},{"issue":"8","key":"2019111904432732300_B17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"issue":"8","key":"2019111904432732300_B18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"issue":"12","key":"2019111904432732300_B19","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nri1729","article-title":"Supernatural T cells: genetic modification of T cells for cancer therapy","volume":"5","author":"Kershaw","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2019111904432732300_B20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjh.13976","article-title":"The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma","volume":"173","author":"Rotolo","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111904432732300_B21","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111904432732300_B22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1535-6108(03)00113-2","article-title":"Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction","volume":"3","author":"Ho","year":"2003","journal-title":"Cancer Cell"},{"issue":"17","key":"2019111904432732300_B23","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111904432732300_B24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jocit.2016.08.001","article-title":"Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective","volume":"2","author":"Smith","year":"2016","journal-title":"Journal of Cellular Immunotherapy."},{"issue":"8","key":"2019111904432732300_B25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019111904432732300_B26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.13889","article-title":"Chimeric antigen receptor (CAR) therapy for multiple myeloma","volume":"172","author":"Atanackovic","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111904432732300_B27","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"issue":"4","key":"2019111904432732300_B28","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"2019111904432732300_B29","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"2019111904432732300_B30","volume-title":"Sci Transl Med","author":"Turtle","year":"2016"},{"issue":"12","key":"2019111904432732300_B31","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"2019111904432732300_B32","volume-title":"J Immunother","author":"Kochenderfer","year":"2009"},{"issue":"20","key":"2019111904432732300_B33","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111904432732300_B34","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111904432732300_B35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.974.974","article-title":"Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma [abstract]","volume":"128","author":"Garfall","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111904432732300_B36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother."},{"issue":"22","key":"2019111904432732300_B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1147.1147","article-title":"B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study [abstract]","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111904432732300_B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.999.999","article-title":"T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial [abstract]","volume":"128","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111904432732300_B39","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"2019111904432732300_B40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"2019111904432732300_B41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev"},{"key":"2019111904432732300_B42","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"26","key":"2019111904432732300_B43","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111904432732300_B44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048]","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2019111904432732300_B45","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"224","key":"2019111904432732300_B46","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2019111904432732300_B47","author":"Brentjens","year":"2013"},{"issue":"16","key":"2019111904432732300_B48","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111904432732300_B49","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"9967","key":"2019111904432732300_B50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"2019111904432732300_B51","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111904432732300_B52","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","article-title":"Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies","volume":"99","author":"Davila","year":"2014","journal-title":"Int J Hematol"},{"issue":"10","key":"2019111904432732300_B53","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111904432732300_B54","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1365-2141.2000.02072-6.x","article-title":"Controversies surrounding the clonogenic origin of multiple myeloma","volume":"110","author":"Davies","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111904432732300_B55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.08.005","article-title":"Cancer stem cells in multiple myeloma","volume":"277","author":"Ghosh","year":"2009","journal-title":"Cancer Lett"},{"issue":"8","key":"2019111904432732300_B56","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/leu.2014.13","article-title":"Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma","volume":"28","author":"Melchor","year":"2014","journal-title":"Leukemia"},{"key":"2019111904432732300_B57","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"5","key":"2019111904432732300_B58","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/leu.2014.321","article-title":"Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential","volume":"29","author":"Pa\u00edno","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2019111904432732300_B59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.12563","article-title":"Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma","volume":"163","author":"Hajek","year":"2013","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111904432732300_B60","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111904432732300_B61","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"20","key":"2019111904432732300_B62","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111904432732300_B63","first-page":"489","article-title":"CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q","volume":"90","author":"Liebisch","year":"2005","journal-title":"Haematologica"},{"issue":"23","key":"2019111904432732300_B64","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1158\/1078-0432.CCR-08-0493","article-title":"Preclinical characterization of SGN-70, a humanized antibody directed against CD70","volume":"14","author":"McEarchern","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111904432732300_B65","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1158\/1078-0432.CCR-16-1421","article-title":"Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2019111904432732300_B66","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111904432732300_B67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood.V76.2.377.377","article-title":"Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19)","volume":"76","author":"Van Camp","year":"1990","journal-title":"Blood"},{"issue":"1","key":"2019111904432732300_B68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2141.1999.01134.x","article-title":"Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression","volume":"104","author":"Rawstron","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111904432732300_B69","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1084\/jem.169.6.2233","article-title":"Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule","volume":"169","author":"Lanier","year":"1989","journal-title":"J Exp Med"},{"issue":"suppl 8","key":"2019111904432732300_B70","article-title":"CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma","volume":"72","author":"Benjamin","year":"2012","journal-title":"Cancer Res"},{"issue":"3","key":"2019111904432732300_B71","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4049\/jimmunol.153.3.952","article-title":"Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule","volume":"153","author":"Dianzani","year":"1994","journal-title":"J Immunol"},{"issue":"4","key":"2019111904432732300_B72","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cyto.b.21092","article-title":"CD38 and CD157: a long journey from activation markers to multifunctional molecules","volume":"84","author":"Quarona","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2019111904432732300_B73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"issue":"6","key":"2019111904432732300_B74","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.V77.6.1218.1218","article-title":"Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells","volume":"77","author":"Terstappen","year":"1991","journal-title":"Blood"},{"issue":"5","key":"2019111904432732300_B75","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/leu.2017.60","article-title":"Monoclonal antibody therapy in multiple myeloma","volume":"31","author":"Touzeau","year":"2017","journal-title":"Leukemia"},{"issue":"13","key":"2019111904432732300_B76","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111904432732300_B77","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/ijms17091506","article-title":"Development of novel immunotherapies for multiple myeloma","volume":"17","author":"Al-Hujaily","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2019111904432732300_B78","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"2019111904432732300_B79","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"issue":"11","key":"2019111904432732300_B80","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111904432732300_B81","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","article-title":"CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms","volume":"121","author":"O\u2019Connell","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2019111904432732300_B82","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3892\/ijo.2012.1545","article-title":"Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide","volume":"41","author":"Kawano","year":"2012","journal-title":"Int J Oncol"},{"key":"2019111904432732300_B83","volume-title":"Blood","author":"Heffner","year":"2012"},{"issue":"6","key":"2019111904432732300_B84","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111904432732300_B85","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"2019111904432732300_B86","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","article-title":"CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications","volume":"25","author":"Treon","year":"2002","journal-title":"J Immunother"},{"issue":"12","key":"2019111904432732300_B87","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nrc1232","article-title":"Applying the principles of stem-cell biology to cancer","volume":"3","author":"Pardal","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2019111904432732300_B88","volume-title":"Clin Cancer Res","author":"Hsi","year":"2008"},{"issue":"15","key":"2019111904432732300_B89","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2019111904432732300_B90","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM family receptors and SAP adaptors in immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"2019111904432732300_B91","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2147\/DDDT.S98053","article-title":"Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma","volume":"11","author":"Friend","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"36","key":"2019111904432732300_B92","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1200\/JCO.2016.69.5908","article-title":"How to integrate elotuzumab and daratumumab into therapy for multiple myeloma","volume":"34","author":"Hofmeister","year":"2016","journal-title":"J Clin Oncol"},{"key":"2019111904432732300_B93","volume-title":"Blood","author":"Danhof","year":"2015"},{"issue":"22","key":"2019111904432732300_B94","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor redirected-T cells against multiple myeloma","volume":"128","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111904432732300_B95","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111904432732300_B96","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"issue":"16","key":"2019111904432732300_B97","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111904432732300_B98","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1158\/0008-5472.CAN-10-0552","article-title":"In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res"},{"issue":"19","key":"2019111904432732300_B99","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111904432732300_B100","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","article-title":"Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells","volume":"155","author":"North","year":"1982","journal-title":"J Exp Med"},{"issue":"7","key":"2019111904432732300_B101","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"2019111904432732300_B102","volume-title":"J Clin Oncol","author":"Berdeja","year":"2017"},{"key":"2019111904432732300_B103","volume-title":"J Clin Oncol","author":"Fan","year":"2017"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/24\/2594\/1404017\/blood793869.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/24\/2594\/1404017\/blood793869.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T03:09:15Z","timestamp":1693019355000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/24\/2594\/36866\/Chimeric-antigen-receptor-Tcell-therapies-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":103,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-06-793869","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}